MicroVue™ CH50 Eq EIA
The MicroVue CH50 Eq EIA measures the total classical complement pathway activity in human serum and allows detection of a deficiency of one or more of the complement components C1 through C9.
Product Specifications
Citations | 17 |
---|---|
Specimen |
Serum 14 μL |
LLOQ | N/A |
ULOQ | N/A |
Assay Time | 3.5 hours |
Cross Reactivity |
Cynomolgous monkey |
Ordering Information
Catalog Number | A018 |
---|---|
Catalog Number (CE) | |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 640,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue CH50 Eq EIA measures the total classical complement pathway activity in human serum and allows detection of a deficiency of one or more of the complement components C1 through C9. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Serum 14 μL |
Limit of Detection (LOD) | N/A |
Lower Limit of Quantitation (LLOQ) | N/A |
Upper Limit of Quantitation (ULOQ) | N/A |
Intra Assay | 3.2–4.5% |
Inter Assay | 5.4–8.7% |
Standards | 5 |
Controls | 2 |
Sample Values |
Normal 133±54 CH50 U Eq/mL |
Assay Time | 3.5 hours |
Cross Reactivity |
Cynomolgous monkey |
Storage |
Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details. |
Background |
The binding of C1q component of C1 to immune complexes triggers the classical complement pathway. This activation results in a cascade of enzymatic and non-enzymatic reactions, culminating in the formation of terminal complement complexes (TCC). Under standard conditions the level of TCC that can be generated in a serum is a quantitative expression of the serum’s total classical complement activity. The traditional method for measuring the total classical complement activity in serum is the CH50 test. This test is a lytic assay, which uses antibody-sensitized sheep erythrocytes (EA) as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis. The percent hemolysis is determined spectrophotometrically. The CH50 test is an indirect measure of TCC, since the TCC themselves are directly responsible for the hemolysis that is measured. The MicroVue CH50 Eq EIA provides a direct measure of the total classical complement activity in serum by quantifying the amount of TCC generated under standard conditions. The MicroVue CH50 Eq EIA uses a monoclonal antibody to a unique neoantigen to capture the TCC analyte. Since both the CH50 Eq EIA and the CH50 test rely on the generation of TCC and correlate, the CH50 Eq EIA’s results are expressed in CH50 unit equivalents per milliliter. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody. |
2020 | ELISA |
Cynomolgus Monkey |
Plasma, Serum |
T-effector cell agonist (OX40) antibody |
Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid. |
2015 | ELISA |
Human |
Serum |
Acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS) |
2020 | ELISA |
Human |
Serum |
HEK 293 Cells incubated |
|
2020 | ELISA |
Human |
Plasma |
Severe Traumatic Bleeding |
|
2021 | ELISA |
Human |
Serum |
COVID-19 |
|
2022 | ELISA |
Human |
Serum |
Chitosan and Hyaluronic Acid-Based Nanohydrogels |
|
2022 | ELISA |
Human |
Serum |
COVID-19 |
|
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease |
2011 | ELISA |
Human |
Serum |
|
2011 | ELISA |
Human |
Plasma |
Lymphatic filariasis |
|
Gene expression changes in human islets exposed to type 1 diabetic serum |
2012 | ELISA |
Human |
Serum |
Islet Cells |
2013 | ELISA |
Human |
Serum |
AamS6 tick protein incubated |
|
Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury |
2013 | ELISA |
Human |
Serum |
OmCI tick protein incubated |
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation |
2016 | ELISA |
Human |
Serum |
|
Host- and pathogen-derived adjuvant coatings on protein nanoparticle vaccines |
2017 | ELISA |
Human |
Serum |
Nanoparticles incubated |
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. |
2023 | ELISA |
Human |
Serum |
COVID-19 |
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid |
2024 | ELISA |
Human |
Serum |
COVID-19 |
Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor |
2010 | ELISA |
Human, Primate |
Serum |